SS-31
Symbol Ss · MW 640 Da
Mitochondria-targeted peptide that stabilizes cardiolipin.
- Discovered
- 2004
- Half-life
- 2 hours
- Approval
- Investigational
Quick facts
- Category
- Longevity
- Route
- Injectable
- Molecular weight
- 640 Da
- Half-life
- 2 hours
- Discovered
- 2004
- Approval status
- Investigational
Reported effects
- Mitochondrial function
- Cardiovascular research
- Cellular energy
Overview
SS-31, also known as Elamipretide, is a mitochondria-targeting peptide studied for mitochondrial function, oxidative stress, and cellular energy production. It is designed to interact with mitochondrial membranes and support healthier energy production at the cellular level. SS-31 is commonly discussed in longevity research because mitochondrial dysfunction is closely linked to aging, fatigue, and degenerative disease processes. Its purpose is to support mitochondrial health, reduce oxidative stress, and improve cellular energy efficiency. As a longevity peptide, SS-31 is best understood as a research-focused compound centered on mitochondrial support and cellular performance.
Evidence context
SS-31 evidence summary
Human clinical evidence
Human clinical evidence for SS-31 may be limited, investigational, region-specific, or unavailable in the local source data. Peptidic avoids treating reported effects as proven clinical outcomes.
Animal, preclinical, or formulation evidence
SS-31 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for SS-31 as Investigational. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- Clinical research ranges vary; commonly studied around 40 mg daily in some subcutaneous trials
- Typical Frequency
- Once daily
There is no established FDA-approved dosage for this peptide. This information is for educational reference only and should not be treated as medical guidance.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on SS-31.
Internal links
Related peptides
Frequently asked questions
What category is SS-31 in?
SS-31 is listed in the Longevity category on Peptidic.
What route is SS-31 associated with?
SS-31 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is SS-31 approved?
Peptidic lists the approval status for SS-31 as: Investigational. Approval details can vary by indication and jurisdiction.
Interested in SS-31?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01